Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 injection in adult type 2 diabetes mellitus (Ib/IIa)
CTR20221509Phase 2Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bofanglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Incidence of adverse events and serious adverse events (Part A) and Change in HbA1c from baseline (Part B). Started Jun 2022; status: completed.
02
Drugs
bofanglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20221509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221509.